Salvaggio Ilaria, Adducci Enrica, Dell'Aquila Lucrezia, Rinaldi Simona, Marini Marco, Zappia Luca, Mascaro Adriana
Anaesthesiology and Intensive Care Institute, Catholic University, Medical School, Rome, Italy.
Pain Med. 2008 Oct;9(7):958-62. doi: 10.1111/j.1526-4637.2008.00515.x.
The goal of the present study is to verify the efficacy of stellate ganglion block (SGB) in the treatment of facial pain that can be found in different pathological syndromes, and also to examine whether the efficacy is dependent upon when this therapy is administered.
Fifty patients (divided into two randomized groups) with facial pain caused by traumas, iatrogenic issues, herpes zoster, or neurological pathologies participated in this study.
The first group (N = 25) was treated with SGB produced by 10 administrations of 10 mg of levobupivacaine given every other day, followed by one administration per month for 6 months thereafter. The second group was treated with the drugs tramadol 100 mg/day and gabapentin 1800 mg/day orally for 6 months; during the 7th month they were given SGB therapy using the same methodology as that described for the first group.
Before treatment, the mean visual analog scale (VAS) pain score for the first group was 8.89; after the 10th block treatment it was just 0.2, and it remained at that reduced level for the 6th and 12th months. Before treatment, the mean VAS pain score for the second group was 8.83; after the 20th day on medication it was reduced to 4.1, after 6 months it was 5.7 and after 12 months it was 4.9.
Our results indicate that patients must be treated with SGB therapy precociously to receive its full benefits.
本研究的目的是验证星状神经节阻滞（SGB）在治疗不同病理综合征所致面部疼痛中的疗效，并探讨疗效是否取决于该疗法的给药时机。
50例因创伤、医源性问题、带状疱疹或神经病理导致面部疼痛的患者（分为两个随机组）参与了本研究。
第一组（N = 25）接受SGB治疗，每隔一天注射10次10mg左旋布比卡因，之后6个月每月注射一次。第二组口服曲马多100mg/天和加巴喷丁1800mg/天，持续6个月；在第7个月，他们接受与第一组相同方法的SGB治疗。
治疗前，第一组的平均视觉模拟量表（VAS）疼痛评分为8.89；在第10次阻滞治疗后仅为0.2，在第6个月和第12个月时保持在该降低水平。治疗前，第二组的平均VAS疼痛评分为8.83；用药第20天后降至4.1，6个月后为5.7，12个月后为4.9。
我们的结果表明，患者必须尽早接受SGB治疗才能充分受益。
